Investment Premium

Jim Simons’ investment office backs fast-growing biotech unicorn


A rapidly growing biotech group that listed on NASDAQ last month with a market capitalisation of more than a billion dollars is backed by Euclidean Capital, the investment office of […]

This is a Premium article. Please subscribe to continue reading.

Leave a Reply

Your email address will not be published. Required fields are marked *